High-Grade Gliomas in Children

Neurosurgery Clinics of North America

Volumn 23, Issue 3, 2012, Pages 515-523

  Cage, Tene A ^a   Mueller, Sabine ^b   Haas Kogan, Daphne ^b   Gupta, Nalin ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anaplastic astrocytoma; Chemotherapy; Glioblastoma multiforme; Pediatric brain tumors; Radiation therapy

Indexed keywords

CANCER VACCINE; CARMUSTINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; IMATINIB; IRINOTECAN; LOMUSTINE; METHOTREXATE; PLATELET DERIVED GROWTH FACTOR RECEPTOR INHIBITOR; PLATINUM COMPLEX; PREDNISONE; PROCARBAZINE; RADIOSENSITIZING AGENT; RECEPTOR BLOCKING AGENT; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; UNCLASSIFIED DRUG; VELIPARIB; VEMURAFENIB; VINCRISTINE; XL 765;

AGE; BRAIN HEMORRHAGE; BRAIN STEM TUMOR; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CELL PROLIFERATION; CHILD; CHILDHOOD CANCER; CHROMOSOME 10Q; CLINICAL FEATURE; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG MEGADOSE; EPENDYMOMA; GENE; GENE MUTATION; GLIA CELL; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; MITOSIS; NEUROLOGICAL COMPLICATION; P53 GENE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PTEN GENE; REVIEW; TREATMENT OUTCOME; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; GENES, P53; GLIOBLASTOMA; HUMANS; INFANT; LOSS OF HETEROZYGOSITY; MALE; NEUROSURGICAL PROCEDURES; PTEN PHOSPHOHYDROLASE; RADIOTHERAPY;

EID: 84863001452     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.04.007     Document Type: Review

References (58)

1. Pollack I.F. Brain tumors in children. N Engl J Med 1994, 331:1500.
2. Kleihues P., Louis D.N., Scheithauer B.W., et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002, 61:215.
3. Tamber M.S., Rutka J.T. Pediatric supratentorial high-grade gliomas. Neurosurg Focus 2003, 14:e1.
4. 2009-2010 CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in eighteen states in 2002-2006 2009, CBTRUS, Central Brain Tumor Registry of the United States, Hinsdale (IL).
5. Perkins S., Rubin J., Leonard J., et al. Glioblastoma in children: a single-institution experience. Int J Radiat Oncol Biol Phys 2011, 80:1117.
6. Pettorini B.L., Park Y.S., Caldarelli M., et al. Radiation-induced brain tumours after central nervous system irradiation in childhood: a review. Childs Nerv Syst 2008, 24:793.
7. Li F.P., Fraumeni J.F., Mulvihill J.J., et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48:5358.
8. Varley J.M., McGown G., Thorncroft M., et al. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 1997, 57:3245.
9. Jouhilahti E., Peltonen S., Heape A., et al. The pathoetiology of neurofibromatosis 1. Am J Pathol 1932, 178:2011.
10. Turcot J., Despres J.P., St Pierre F. Malignant tumors of the central nervous system associated with familial polyposis of the colon: report of two cases. Dis Colon Rectum 1959, 2:465.
11. Lusis E., Travers S., Jost S., et al. Glioblastomas with giant cell and sarcomatous features in patients with Turcot syndrome type 1: a clinicopathological study of 3 cases. Neurosurgery 2010, 67:811.
12. Felsberg J., Thon N., Eigenbrod S., et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 2011, 129:659.
13. Ranger A., Szymczak A., Hammond R., et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. J Neurosurg Pediatr 2009, 4:363.
14. Pfister S., Witt O. Pediatric gliomas. Recent results. Cancer Res 2009, 171:67.
15. Pollack I.F., Hamilton R.L., James C.D., et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg 2006, 105:418.
16. Pollack I.F., Finkelstein S.D., Burnham J., et al. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res 2001, 61:7404.
17. Pollack I.F., Finkelstein S.D., Woods J., et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 2002, 346:420.
18. Bredel M., Pollack I.F., Hamilton R.L., et al. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 1999, 5:1786.
19. Nakamura M., Shimada K., Ishida E., et al. Molecular pathogenesis of pediatric astrocytic tumors. Neuro Oncol 2007, 9:113.
20. Faury D., Nantel A., Dunn S., et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 2007, 25:1196.
21. Liu W., James C.D., Frederick L., et al. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 1997, 57:5254.
22. Pollack I.F., Hamilton R.L., Burnham J., et al. Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort. Neurosurgery 2002, 50:1238.
23. Rickert C., Strater R., Kaatsch P., et al. Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. Am J Pathol 2001, 158:1525.
24. Sung T., Miller D.H., Hayes R.L., et al. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 2000, 10:249.
25. Mehta V., Chapman A., McNeely P.D., et al. Latency between symptom onset and diagnosis of pediatric brain tumors: an Eastern Canadian geographic study. Neurosurgery 2002, 51:365.
26. Duffner P.K. Diagnosis of brain tumors in children. Expert Rev Neurother 2007, 7:875.
27. Osborn A., Blaser S., Salzman K., et al. Diagnostic imaging brain 2007, Amirsys, Salt Lake City (UT).
28. Steffen-Smith E., Shih J., Hipp S., et al. Proton magnetic resonance spectroscopy predicts survival in children with diffuse intrinsic pontine glioma. J Neurooncol 2011, 105:365.
29. Finlay J.L., Boyett J.M., Yates A.J., et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol 1995, 13:112.
30. Heideman R.L., Kuttesch J., Gajjar A.J., et al. Supratentorial malignant gliomas in childhood: a single institution perspective. Cancer 1997, 80:497.
31. Wolff J.E., Gnekow A.K., Kortmann R.D., et al. Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer 2002, 94:264.
32. Wisoff J.H., Boyett J.M., Berger M.S., et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg 1998, 89:52.
33. Hyder D., Sung L., Pollack I., et al. Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience. J Neurooncol 2007, 83:1.
34. Fulton D.S., Urtasun R.C., Scott-Brown I., et al. Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study. J Neurooncol 1992, 14:63.
35. Packer R.J., Boyett J.M., Zimmerman R.A., et al. Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. A Childrens Cancer Group Phase I/II Trial. Cancer 1993, 72:1414.
36. Sposto R., Ertel I.J., Jenkin R.D., et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol 1989, 7:165.
37. Stupp R., Dietrich P.Y., Ostermann Kraljevic S., et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002, 20:1375.
38. Cohen B.H., Zeltzer P.M., Boyett J.M., et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group randomized trial. J Clin Oncol 1995, 13:1687.
39. Cohen K., Pollack I., Zhou T., et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol 2011, 13:317.
40. Cohen K., Heideman R., Zhou T., et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol 2011, 13:410.
41. Nicholson H.S., Kretschmar C.S., Krailo M., et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 2007, 110:1542.
42. Lashford L.S., Thiesse P., Jouvet A., et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 2002, 20:4684.
43. Estlin E.J., Lashford L., Ablett S., et al. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer 1998, 78:652.
44. Grovas A.C., Boyett J.M., Lindsley K., et al. Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group. Med Pediatr Oncol 1999, 33:83.
45. Massimino M., Gandola L., Luksch R., et al. Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro Oncol 2005, 7:41.
46. Marachelian A., Butturini A., Finlay J. Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors. Bone Marrow Transplant 2008, 41:167.
47. Wolff J., Driever P., Erdlenbruch B., et al. Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer 2010, 116:705.
48. Pollack I. Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. J Neurosurg Pediatr 2011, 8:135.
49. Bax D., Gaspar N., Little S., et al. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res 2009, 15:5753.
50. Schiffman J., Hodgson J., VandenBerg S., et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 2010, 70:512.
51. Nicolaides T., Li H., Solomon D., et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res 2011, 17:7595.
52. Flaherty K., Puzanov I., Kim K., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809.
53. Gadji M., Crous A., Fortin D., et al. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts. Eur J Pharmacol 2009, 625:23.
54. Pollack I.F., Jakacki R.I., Blaney S.M., et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol 2007, 9:145.
55. Wolff J., Kortmann R., Wolff B., et al. High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study. J Neurooncol 2011, 102:433.
56. van Vuurden D., Hulleman E., Meijer O., et al. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2011, 2:984.
57. Ardon H., De Vleeschouwer S., Van Calenbergh F., et al. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer 2010, 54:519.
58. Hatziagapiou K., Braoudaki M., Karpusas M., et al. Evaluation of antitumor activity of gefitinib in pediatric glioblastoma and neuroblastoma cells. Clin Lab 2011, 57:781.